Program
Memantine
Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.
Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.
Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 130 open or running | phase 4since Jun 6, 2006 | Dec 1, 2004 | none ahead |
| H. Lundbeckits history only | 60 open or running | phase 4since Mar 3, 2009 | Mar 3, 2009 | none ahead |
| Merz Pharmaits history only | 40 open or running | phase 4since Mar 27, 2008 | Feb 14, 2008 | none ahead |
| Carnot Laboratoriesits history only | 10 open or running | phase 4since Feb 11, 2026 | Feb 11, 2026 | none ahead |
| Gedeon Richter Plc. | 10 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Apr 18, 2017 | Apr 18, 2017 | none ahead |
| Mendel AIits history only | 10 open or running | phase 3since Jan 30, 2021 | Jan 30, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gedeon Richter Plc. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 15, 2013First study: phase 1 study in ObesityFirst studyNCT02001584 · United Kingdom
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
Studies
The one study Gedeon Richter Plc. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02001584Obesity · United Kingdom | 1 | Completed | May 2014 |
How it is read
Names in the registry
- “Memantine”, 11 entries
- “Memantine Hydrochloride (HCl)”, 4 entries
- “memantine”, 3 entries
- “memantine HCl”, 3 entries
- “Memantine HCl”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 14 studies
- Autistic Disorder, 3 studies
- Autism Spectrum Disorder, 2 studies
- Glaucoma, Open-Angle, 2 studies
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.